Differentiation syndrome is a potentially life-threatening complication that can occur during the treatment of certain types of cancers, particularly acute promyelocytic leukemia (APL). This syndrome is typically associated with the use of differentiating agents such as all-trans retinoic acid (ATRA) and arsenic trioxide. These agents induce cancer cells to mature into normal blood cells, but this rapid differentiation can lead to a cascade of inflammatory responses and other complications.
